{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:38:08Z","timestamp":1788871088094,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","award":["H23-008"],"award-info":[{"award-number":["H23-008"]}],"id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.psychres.2013.07.005","type":"journal-article","created":{"date-parts":[[2013,8,4]],"date-time":"2013-08-04T04:46:31Z","timestamp":1375591591000},"page":"396-401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia"],"prefix":"10.1016","volume":"210","author":[{"given":"Kotaro","family":"Hatta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takebayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemasa","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kasuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyoshi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Nakase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Kuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Ohnuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2013.07.005_bib1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mp.2011.38","article-title":"Genetic variation in CYP3A43 explains racial difference in olanzapine clearance","volume":"16","author":"Bigos","year":"2011","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.psychres.2013.07.005_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1192\/bjp.bp.105.015701","article-title":"Brain volume changes in the first year of illness and 5-year outcome of schizophrenia","volume":"189","author":"Cahn","year":"2006","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2013.07.005_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.psychres.2013.07.005_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1176\/ps.2007.58.1.11","article-title":"Datapoints: the ups and downs of dosing second-generation antipsychotics","volume":"58","author":"Citrome","year":"2007","journal-title":"Psychiatric Services"},{"key":"10.1016\/j.psychres.2013.07.005_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","article-title":"Olanzapine plasma concentrations after treatment with 10, 20, and 40mg\/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration","volume":"29","author":"Citrome","year":"2009","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2013.07.005_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.9758\/cpn.2011.9.1.17","article-title":"Antipsychotics prescribing patterns of patients with schizophrenia admitted to Korean general hospital psychiatric unit: 2001 to 2008","volume":"9","author":"Choi","year":"2011","journal-title":"Clinical Psychopharmacology and Neuroscience"},{"key":"10.1016\/j.psychres.2013.07.005_bib7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2013.07.005_bib8","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.psychres.2013.07.005_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0163-8343(02)00252-9","article-title":"Acute-phase treatment in general hospitals: clinical psychopharmacologic evaluation in first-episode schizophrenia patients","volume":"25","author":"Hatta","year":"2003","journal-title":"General Hospital Psychiatry"},{"key":"10.1016\/j.psychres.2013.07.005_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2011.02.011","article-title":"Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia","volume":"128","author":"Hatta","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2013.07.005_bib11","doi-asserted-by":"crossref","unstructured":"Hatta, K., Otachi, T., Sudo, Y., Kuga, H., Takebayashi, H., Hayashi, H., Ishii, R., Kasuya, M., Hayakawa, T., Morikawa, F., Hata, K., Nakamura, M., Usui, C., Nakamura, H., Hirata, T., Sawa, Y., 2012. A Comparison Between Augmentation with Olanzapine and Increased Risperidone Dose in Acute Schizophrenia Patients Showing Early Non-response to Risperidone. Psychiatry Research Mar. 13. (Epub ahead of print] PMID: 22421064). For the JAST Study Group.","DOI":"10.1016\/j.psychres.2012.01.006"},{"key":"10.1016\/j.psychres.2013.07.005_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.schres.2009.05.030","article-title":"Effectiveness of second-generation antipsychotics with acute-phase schizophrenia","volume":"113","author":"Hatta","year":"2009","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2013.07.005_bib13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s004060050036","article-title":"Abnormal physiological conditions in acute schizophrenic patients on emergency admission: dehydration, hypokalemia, leukocytosis and elevated serum muscle enzymes","volume":"248","author":"Hatta","year":"1998","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1016\/j.psychres.2013.07.005_bib14","series-title":"Evaluation and Diagnosis of Drug-induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage","author":"Inada","year":"1996"},{"issue":"5","key":"10.1016\/j.psychres.2013.07.005_bib15","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1192\/bjp.166.5.654","article-title":"A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF)","volume":"166","author":"Jones","year":"1995","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2013.07.005_bib16","series-title":"Positive and Negative Syndrome Scale (PANSS) Rating Manual","author":"Kay","year":"1991"},{"key":"10.1016\/j.psychres.2013.07.005_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/hup.781","article-title":"Plasma concentrations of high-dose olanzapine in a double-blind crossover study","volume":"21","author":"Kelly","year":"2006","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1016\/j.psychres.2013.07.005_bib18","first-page":"365","article-title":"Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects","volume":"29","author":"Kinon","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1016\/j.psychres.2013.07.005_bib19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JCP.0b013e31817e63a5","article-title":"Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study","volume":"28","author":"Kinon","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2013.07.005_bib20","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.4088\/JCP.v66n1211","article-title":"Olanzapine versus risperidone in newly admitted acutely ill psychotic patients","volume":"66","author":"Kraus","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2013.07.005_bib21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopsych.2007.04.043","article-title":"Clozapine and \u201chigh-dose\u201d olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison","volume":"63","author":"Kumra","year":"2008","journal-title":"Biological Psychiatry"},{"issue":"Suppl 438","key":"10.1016\/j.psychres.2013.07.005_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","article-title":"Definitions of response and remission in schizophrenia: recommendations for their use and their presentation","volume":"119","author":"Leucht","year":"2009","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.psychres.2013.07.005_bib23","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.psychres.2013.07.005_bib24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response","volume":"46","author":"Mauri","year":"2007","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.psychres.2013.07.005_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1192\/bjp.bp.105.019307","article-title":"Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia","volume":"189","author":"McCue","year":"2006","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2013.07.005_bib26","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.clinthera.2006.06.008","article-title":"A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40mg\/d oral olanzapine relative to 20mg\/d oral olanzapine in stable psychiatric subjects","volume":"28","author":"Mitchell","year":"2006","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.psychres.2013.07.005_bib27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4088\/JCP.v69n0214","article-title":"A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia","volume":"69","author":"Meltzer","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2013.07.005_bib28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4088\/JCP.v69n0201","article-title":"High-dose olanzapine for treatment-resistant schizophrenia","volume":"69","author":"Roth","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2013.07.005_bib29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/JCP.0b013e318204d9e2","article-title":"High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug","volume":"31","author":"Skogh","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2013.07.005_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2011.09.016","article-title":"Treatment resistant schizophrenia and response to antipsychotics: a review","volume":"133","author":"Suzuki","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2013.07.005_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder","volume":"159","author":"Volavka","year":"2002","journal-title":"American Journal of Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178113003806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178113003806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:21:49Z","timestamp":1759036909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178113003806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0165178113003806"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2013.07.005","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2013.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}